Cytori Therapeutics Inc. is a cell therapy company dedicated primarily to the development of novel treatments for cardiovascular disease and soft tissue injuries and burns. The company has a global product development strategy focused on the U.S. cardiovascular disease market. In the U.S., its goal is to bring its cell therapy to market for treatment of chronic ischemic heart failure through Cytori-sponsored clinical development efforts and to develop a treatment for thermal burns combined with radiation injury under a contract from BARDA, a division of the U.S. Department of Health and Human Services.